Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3560130

COc1ccccc1-c1cn(S(=O)(=O)c2ccc(C)cc2)c2ncc(-c3ccc(N)c(C(=O)O)c3)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 3/20 0.47
MAP4K1 Q92918 1/20 0.43
MAPT P10636 3/20 0.42
TSHR P16473 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
SLC1A3 P43003 3/20 0.40
SLC1A2 P43004 3/20 0.40
SLC1A1 P43005 3/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SYK P43405 4/20 0.37
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
PI4KA P42356 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13342637 0.95 PTPN11 (0.51) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3560133 0.90 PTPN11 (0.43) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3561085 0.87 PTPN11 (0.44) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3565148 0.87 MAP4K1 (0.59) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3568791 0.86 PTPN11 (0.47) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3569080 0.84 PTPN11 (0.47) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3564256 0.84 PTPN11 (0.43) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL13368497 0.84 MAPT (0.47) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3568123 0.84 PTPN11 (0.48) PTPN11MAP4K1MAPTTSHRSMN1; SMN2
SCHEMBL3414082 0.83 TSHR (0.46) PTPN11MAP4K1MAPTTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
EP-2134343-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 PTPN11 1303/4885MAP4K1 3/4885MAPT 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.